Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Interstitial Cystitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00056251
Recruitment Status : Completed
First Posted : March 10, 2003
Last Update Posted : June 24, 2005
Sponsor:
Information provided by:
ICOS Corporation

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Patients with interstitial cystitis who meet eligibility requirements will be randomized to one of four treatment arms (3 RTX, Placebo). Study drug is administered as a single instillation within the urinary bladder. Study duration is 12 weeks.

Condition or disease Intervention/treatment Phase
Interstitial Cystitis Procedure: H&P; ECG; Blood tests; voiding diary; Cystoscopy Phase 2

Detailed Description:

RATIONALE:

Topical resiniferatoxin (RTX) administrated to the bladder may be effective in decreasing the symptoms associated with interstitial cystitis through its action on pain sensing neurons.

PURPOSE:

Randomized, double-blind, placebo-controlled, Phase 2 trial to determine the safety and efficacy of RTX in patients with interstitial cystitis.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of RTX Topical Solution in Patients With Interstitial Cystitis
Study Start Date : January 2003
Study Completion Date : August 2003

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥ 18 years of age.
  • Have IC that meets disease diagnostic criteria as defined by a history of the following:
  • Cystoscopy/hydrodistension with a diagnosis of IC confirmed by findings of Hunner's ulcer or glomerulation
  • Symptoms of bladder pain and urinary urgency for at least 6 months
  • Urinary frequency while awake at least 8 times a day while awake
  • Nocturia at least twice a night
  • Symptoms not significantly relieved by antimicrobial agents, anticholinergic drugs, or antispasmodics
  • Have IC that in the judgment of the investigator has been stable in the previous 30 days
  • Have IC-related pain despite current therapy, defined as a score of 4 or greater [(on a scale from 0 (none) to 9 (severe)] on average over the past month and confirmed by the voiding diary collected at Visit 2
  • Have at least one voided volume ≥ 75 cc in a 24 hour period, confirmed by the voiding diary collected at Visit 2
  • Patients of childbearing potential must agree to use an acceptable form of contraception (oral contraceptives, intrauterine device or double barrier methods) from Visit 1 through Visit 6
  • Provide signed informed consent

Exclusion Criteria:

  • Currently pregnant or breastfeeding
  • Presence of ulcers on the pre-treatment cystoscopy
  • Intravesical therapy or bladder hydrodistention within the previous 60 days
  • Initiation of pentosan polysulfate sodium (Elmiron®) within the previous 16 weeks
  • Use of fentanyl patches, morphine sulfate, methadone or B&O supprettes within the previous 30 days.
  • Previous augmentation cystoplasty, cystectomy or cystolysis, neurectomy (i.e., hypogastric nerve plexus ablation) or implanted peripheral nerve stimulator which has affected bladder function
  • History of ureteral reflux. Patients with a history of childhood urinary tract infections, recurrent urinary tract infections as an adult (defined as >3 culture documented episodes within the previous 12 months), or pyelonephritis at any time must have a cystourethogram to rule out ureteral reflux.
  • Evidence of renal impairment (creatinine > 2 times the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > 3 times the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases
  • Any condition that in the judgment of the investigator would interfere with the patient's ability to provide informed consent, comply with study instructions, place the patient at increased risk, or which might confound the interpretation of the study results
  • Treatment with a drug or medical device that has not received regulatory approval within the previous 30 days
  • Investigators, study staff and their immediate families. Immediate family is defined as current spouse, parent, natural or legally adopted child (including a stepchild living in the investigator's household), grandparent, or grandchild.
  • Previously completed or withdrawn from this study
  • Urinary tract or prostatic infection within the past 3 months before study entry
  • Active genital herpes or vaginitis
  • Urethral diverticulum
  • Uterine, cervical, vaginal, or urethral cancer within the past 5 years before study entry
  • History of cyclophosphamide or chemical cystitis, urinary tuberculosis or radiation cystitis
  • History of bladder tumors (benign or malignant)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00056251


Locations
Show Show 24 study locations
Sponsors and Collaborators
ICOS Corporation
Investigators
Layout table for investigator information
Study Director: Lyn Frumkin, M.D., Ph.D. ICOS Corporation, (425) 415-5571, lfrumkin@icos.com
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00056251    
Other Study ID Numbers: JIC01
First Posted: March 10, 2003    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: January 2004
Keywords provided by ICOS Corporation:
Interstitial Cystitis
Bladder
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystitis
Cystitis, Interstitial
Urinary Bladder Diseases
Urologic Diseases